CNTY-101
- Generic Name
- CNTY-101
A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases
Phase 1
Recruiting
- Conditions
- Systemic Lupus ErythematosusLupus NephritisIdiopathic Inflammatory MyopathiesDiffuse Cutaneous Systemic Sclerosis
- Interventions
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Century Therapeutics, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT06255028
- Locations
- 🇺🇸
Keck School of Medicine of University of Southern California, Los Angeles, California, United States
🇺🇸UC Davis, Sacramento, California, United States
🇺🇸Lurie Children's; Northwestern Medicine - Northwestern Medical Group, Chicago, Illinois, United States
A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies
Phase 1
Active, not recruiting
- Conditions
- Aggressive Non-Hodgkin LymphomaIndolent Non-Hodgkin LymphomaR/R CD19-Positive B-Cell Malignancies
- Interventions
- First Posted Date
- 2022-04-20
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Century Therapeutics, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT05336409
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸University of Southern California - Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University of California San Diego, Moores Cancer Center, San Diego, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath